## TABLE OF CONTENTS

### HIGHLIGHTS

453  
Selected Articles from This Issue

### REVIEW

455  
**Salting the Soil: Targeting the Microenvironment of Brain Metastases**  
Ethan S. Srinivasan, Aaron C. Tan, Carey K. Anders, Ann Marie Pendergast, Dorothy A. Sipkins, David M. Ashley, Peter E. Fecci, and Mustafa Khasraw

### SMALL MOLECULE THERAPEUTICS

467  
**Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor**  
Aaron Balog, Tai-an Lin, Derrick Maley, Johnni Gullo-Brown, Enzo Hamza Kandoussi, Jianing Zeng, and John T. Hunt

477  
**A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorogenesis, and Metastasis in Aneuploid Cancers**  
Masanori Kawakami, Lisa Maria Mustachio, Yulong Chen, Zibo Chen, Xiaxia Liu, Cheng-Hsin Wei, Jason Roszik, Adam S. Kittai, Alexey V. Danilov, Xiaoshan Zhang, Bingliang Fang, Jing Wang, John V. Heymach, Liliya Tyutyunyk-Massey, Sarah J. Freemantle, Jonathan M. Kurie, Xi Liu, and Ethan Dmitrovsky

490  
**Effects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC Resistant to Second-Line Antiandrogen Therapy**  
Geun Taek Lee, Naoya Nagaya, Jenny Desantis, Kiran Madura, Hatem E. Sabaawy, Wun-Jae Kim, Roy J. Maz, Gabrielle Cruciani, and Isaac Yi Kim

500  
**The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell–Mediated Immunotherapies**  
Sruthy Varghese, Snigdha Pramanik, Leila J. Williams, Hannah R. Hodges, Courtney W. Hudgens, Grant M. Fischer, Catherine K. Luo, Barbara Knighton, Lin Tan, Philip L. Lorenzi, Andrew L. Mackinnon, Jennifer L. McQuade, Yared Hailemichael, Jason Roszik, Wei Yi Peng, and Y.N. Vashisht Gopal

512  
**Immunotherapy with Immunocytokines and PD-1 Blockade Enhances the Anticancer Activity of Small Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX**  
Jacopo Millul, Christiane Krudewig, Aureliano Zana, Sheila Dakhel Plaza, Emanuele Puca, Alessandra Villa, Dario Neri, and Samuele Cazzamalli

### LARGE MOLECULE THERAPEUTICS

523  
**Exosome Surface Display of IL12 Results in Tumor-Retained Pharmacology with Superior Potency and Limited Systemic Exposure Compared with Recombinant IL12**  
Nuruddeen D. Lewis, Chang Ling Sia, Katherine Kirwin, Sonya Haupt, Gauri Mahimkar, Tong Zl, Ke Xu, Kevin Dooley, Su Chul Jang, Bryan Choi, Adam Boutin, Andrew Grube, Christine McCoy, Jorge Sanchez-Salazar, Michael Doherty, Leonid Gaidukov, Scott Estes, Kyriakos D. Economides, Douglas E. Williams, and Sriman Sathyarayanan

535  
**ABBV-085, Antibody–Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium**  
Pooja Hingorani, Michael E. Roth, Yifei Wang, Wendong Zhang, Jonathan B. Gill, Douglas J. Harrison, Beverly Teicher, Stephen Erickson, Gregory Gatto, Malcolm A. Smith, Edward A. Kolb, and Richard Gorlick

541  
**Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATR**  
TABLE OF CONTENTS

553 Improved Antitumor Activity of the Fluoropyrimidine Polymer CF10 in Preclinical Colorectal Cancer Models through Distinct Mechanistic and Pharmacologic Properties
William H. Gmeiner, Anthony Dominijanni, Alex O. Haber, Lais P. Ghiraldeli, David L. Caudell, Ralph D’Agostino Jr, Boris C. Pasche, Thomas L. Smith, Zhiyong Deng, Sezgin Kiren, Chinnadurai Mani, Komaraiah Palle, and Jonathan R. Brody

COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS

564 Identification of Predictive ERBB Mutations by Leveraging Publicly Available Cell Line Databases
Marika K.A. Koivu, Deepankar Chakroborty, Mahlet Z. Tamirat, Mark S. Johnson, Kari J. Kurppa, and Klaus Elenius

CANCER BIOLOGY AND TRANSLATIONAL STUDIES

577 Targeting Radiation-Resistant Prostate Cancer Stem Cells by B7-H3 CAR T Cells
Yida Zhang, Lile He, Ananthan Sadagopan, Tao Ma, Gianpietro Dotti, Yufeng Wang, Hui Zheng, Xin Gao, Dian Wang, Albert B. DeLeo, Song Fan, Ruochuan Sun, Ling Yu, Liyuan Zhang, Gongxian Wang, Soldano Ferrone, and Xinhui Wang

589 Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors
Amy Kwan, Natalie Winder, Emer Atkinson, Haider Al-Janabi, Richard J. Allen, Russell Hughes, Mohammed Moamin, Rikah Louie, Dhanajay Evans, Matthew Hutchinson, Drew Capper, Katie Cox, Joshua Handley, Adam Wilshaw, Taewoo Kim, Simon J. Tazzym, Sanjay Srivastava, Penelope Ottewell, Jayakumar Vadakekolathu, Graham Pockley, Claire E. Lewis, Janet E. Brown, Sarah J. Danson, Joe Conner, and Munitta Muthana

602 Neutralization of TGFβ Improves Tumor Immunity and Reduces Tumor Progression in Ovarian Carcinoma
Brandon M. Roane, Selene Meza-Perez, Ashwini A. Katre, Whitney N. Goldsberry, Troy D. Randall, Lyse A. Norian, Michael J. Birrer, and Rebecca C. Arend

612 The Histone Methyltransferase Gene G9A Is Regulated by Nuclear Receptor 4A1 in Alveolar Rhabdomyosarcoma Cells
Rupesh Shrestha, Kumaravel Mohankumar, Un-ho Jin, Gregory Martin, and Stephen Safe

ABOUT THE COVER
Photomicrographic image of a tumor invasive margin from a syngeneic tumor model (MC38) stained with multiplex immunofluorescence to identify macrophages (F4/80⁺; Red) in the tumor microenvironment. Polarization state of these macrophages was determined using inducible nitric oxide synthase (iNOS; Green), a marker for M1 polarization, and arginase I (Arg1; Cyan) a marker for M2 polarization. In the tumor margins, 152-fold increase in M1 macrophages were observed with exoIL-12 treatment. These studies provide evidence that exoIL-12 was significantly more potent than rIL12 and enabled systemic anti-tumor immunity by facilitating prolonged local pharmacology and undetectable systemic exposure. The improved therapeutic index achieved in pre-clinical models support further clinical investigation of this powerful cytokine. Read the full article on p. 523.